HCM News: Johnson Fistel Encourages Shareholders to Contact the Firm Regarding Investigation
SAN DIEGO, May 3, 2022 (GlobeNewsWire)—Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether HUTCHMED (China) Limited (HCM), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focus on investors’ losses and whether they may be recovered under the federal securities laws.
What if I purchased HUTCHMED common stock? If you purchased HUTCHMED common stock and suffered significant losses on your investment, join our investigation now:
· Or for more information, contact Jim Baker at email@example.com or (619) 814-4471
There is no cost or obligation to you.
What is Johnson Fistel investigating? On May 2, 2022, Hutchmed announced that the U.S. Food and Drug Administration (“FDA”) rejected Hutchmed’s application seeking approval of surufatinib to treat certain neuroendocrine tumors, noting that the data submitted did not support an approval and a multi-regional clinical trial is required.
What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or firstname.lastname@example.org.
About Johnson Fistel, LLP. Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in securities class action and derivative lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst